|Acute Kidney Injury (AKI)||Anemia|
|Chronic Kidney Disease (CKD)||Contrast Nephropathy|
|Cardiovascular Disease (CVD)||Diabetes|
|Lupus Nephritis||Peritoneal Dialysis|
Patients are more likely to receive a kidney transplant and less likely to die than patients with end-stage renal disease from other causes.
Study showed that 1 in 20 older adults who initiated these medications in the outpatient setting were hospitalized with AKI within 90 days.
Black female hemodialysis patients less likely to want living transplant; more likely to receive offer.
Proteinuria, hypertension, and obesity in adolescence independently predict development of end-stage renal disease.
The association is most pronounced in hypertensives, consumers of high-sodium diets, and older individuals.
Second review shows value in CKD with suspected ACS, limited by variable sensitivity/specificity.
Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.
Invokamet combines in a single table canagliflozin and metformin.
Researchers find an independent association in a study of Japanese patients with type 2 diabetes.
The finding is from a study of more than 5 million Norwegians.
Increased long-term mortality risk for patients with, but not those without, chronic kidney disease.
Composite of mortality, end-stage renal disease increased at higher and lower blood pressures.
Reasons for taking on additional roles include paying off debt, increasing income, new challenge.
Model including temperature, ultrasonographic findings, etiologic organisms predicts scarring.
Quality improvements protect patients undergoing percutaneous coronary intervention.
Blocks reabsorption of glucose by kidneys.
For some highly sensitized patients, expanded criteria donor kidneys do not confer a survival edge over standard criteria donor kidneys.
Kidney transplanted from brain-dead donors or those who died from circulatory causes are associated with similar patient and graft survival.
Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients.
Study compared single-dose alemtuzumab and multiple-dose rabbit anti-thymocyte globulin.